Drug search by name

Ocaliva and Liver impairment

Result of checking the interaction of drug Ocaliva and disease Liver impairment for safety when used together.

Check result:

Ocaliva <> Liver impairment

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

In postmarketing reports, hepatic decompensation and failure, in some cases fatal, have been reported in patients with primary biliary cholangitis (PBC) with decompensated cirrhosis or Child-Pugh Class B or C hepatic impairment when obeticholic acid was dosed more frequently than recommended. The recommended starting dosage is 5 mg once weekly for patients with Child-Pugh Class B or C hepatic impairment or a prior hepatic decompensation event. Patients in treatment should be closely monitored for progression of PBC disease, including liver- related complications, with laboratory and clinical assessments. Dosage adjustment, interruption or discontinuation may be required.

Ocaliva

Generic Name: obeticholic acid

Brand Name: Ocaliva

Synonyms: n.a.

What is Ocaliva?